Although PRIMA-1 was originally known as a p53 reactivating drug that can rescue the function of mutant forms of p53 by interacting with p53 core domain [41], we found that this drug was able to increase cell death in all three tumor cell lines expressing wild-type p53. The gene discussed is TP53; the disease is neoplasm.